Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

Mums and their newborns will now have free access to protection against RSV. ‘We are going to be perfect friends’: Donald ...

In 2025, eligible pregnant women will be able to receive the respiratory syncytial virus (RSV) vaccine for free under the ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The federal government will spend more than $174 million to give pregnant women a free vaccine for RSV ahead of next year’s ...

The federal government will place RSV vaccines on the national immunisation program, as 12,000 babies are hospitalised with ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...